Fremanezumab in the Prevention of High-Frequency Episodic and Chronic Migraine: A 12-Week, Multicenter, Real-Life, Cohort Study (The FRIEND Study).
Piero Barbanti(Vita-Salute San Raffaele University), Fabrizio Vernieri(Università Campus Bio-Medico), Maria Albanese(University of Rome Tor Vergata), Francesco Bono(Azienda Ospedaliero Universitario Mater Domini), Stefano Bonassi(San Raffaele University of Rome), Maurizio Zucco(Azienda Ospedaliera San Camillo-Forlanini), Ilaria Cetta(Vita-Salute San Raffaele University), Claudia Altamura(Università Campus Bio-Medico), Gabriella Egeo(IRCCS Ospedale San Raffaele), Stefania Proietti(San Raffaele University of Rome), Paola Di Fiore(Ospedale San Carlo), Massimo Filippi(Vita-Salute San Raffaele University), Florindo d’Onofrio, Cinzia Aurilia(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 6
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k
HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2002|1.4k